Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
MacroGenics pulls plug on ADC after seeing phase 2 survival data
MacroGenics has made the call to abandon work on one of its more advanced antibody-drug conjugates after taking a look at the latest phase 2 data.
James Waldron
Mar 21, 2025 7:15am
Monte Rosa's broad molecular glue degrader plan comes unstuck
Mar 20, 2025 10:07am
Pfizer shares prostate cancer data after leak, inks Alloy deal
Feb 11, 2025 1:07pm
Sanofi-backed radiopharma AdvanCell secures $112M series C
Feb 3, 2025 9:00am
Imaging AI developer Quibim nets $50M, eyes US expansion
Jan 30, 2025 1:00pm
Francis Med nets $80M for water vapor prostate cancer therapy
Jan 8, 2025 12:02pm
